Skip to main content

WST West Pharmaceutical Services, Inc.

Healthcare

412.62 Close 10/30
Since 2024-12-02 +28.6%
Open
419.06
High
422.08
Low
407.67
Prev close
416.67
Volume
1.1M
Amplitude
3.46%
P/E
46.3
P/B
9.7
Revenue YoY (TTM)
+12.6%
52W 223.83 438.27

Is West Pharmaceutical Services, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Good, Growth: Good, Momentum: Strong, Risk / liquidity: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 46.31 81th percentile Expensive
Price / book 9.68 92th percentile Expensive
Free-cash-flow yield (%) 1.58 53th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good ROE, TTM is Top; FCF margin, TTM is Good.
ROE, TTM (%) 21.52 83th percentile Top
Operating margin, TTM (%) 22.97 75th percentile Good
FCF margin, TTM (%) 13.35 67th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Good All 2 indicators are Good.
Revenue growth, TTM YoY (%) 12.58 65th percentile Good
Diluted EPS growth, TTM YoY (%) 31.8 72th percentile Good
Momentum Strong All 2 indicators are Top.
60-day return (%) 18.36 91th percentile Top
240-day return (%) 58.24 89th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Strong 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 246,871,143 94th percentile Top
60-day annualized volatility (%) 20.58 22th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

West Pharmaceutical Services, Inc. (WST) today

4 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From West Pharmaceutical Services, Inc. to every stock like it

AI finds several complementary traits of West Pharmaceutical Services, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. (WST) peers and tracking

Watchlist

This page refreshes daily after the close. Add West Pharmaceutical Services, Inc. to your watchlist to track signal changes on your next visit.

West Pharmaceutical Services, Inc. (WST) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

26 historical occurrences (since 2017-01-04)

Average forward return after 52-week adjusted-price high

20-day: Win 46.2%, Sample 26, Median -0.56%, Excess +0.59%, Beat mkt rate 50%

60-day: Win 52%, Sample 25, Median +1.48%, Excess +1.22%, Beat mkt rate 48%

120-day: Win 66.7%, Sample 24, Median +9%, Excess +6.08%, Beat mkt rate 50%

120 days after: historical avg +11.65%

20-day +1.08%
60-day +3.51%
120-day +11.65%
20-day
60-day
120-day
Win
46.2%
52%
66.7%
Sample
26
25
24
Median
-0.56%
+1.48%
+9%
Excess
+0.59%
+1.22%
+6.08%
Beat mkt rate
50%
48%
50%

Over 24 occurrences, 120-day forward avg gained 11.65%, beat the market by 6.08 pts; win rate 66.7%.

Top-quintile 6-month momentum

Active · now 87.52%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
17 historical occurrences (since 2016-07-05)

Average forward return after Top-quintile 6-month momentum

20-day: Win 82.4%, Sample 17, Median +4.2%, Excess +1.23%, Beat mkt rate 58.8%

60-day: Win 64.7%, Sample 17, Median +1.48%, Excess +0.17%, Beat mkt rate 35.3%

120-day: Win 81.2%, Sample 16, Median +9.63%, Excess +5.94%, Beat mkt rate 50%

120 days after: historical avg +13.41%

20-day +3.57%
60-day +4.75%
120-day +13.41%
20-day
60-day
120-day
Win
82.4%
64.7%
81.2%
Sample
17
17
16
Median
+4.2%
+1.48%
+9.63%
Excess
+1.23%
+0.17%
+5.94%
Beat mkt rate
58.8%
35.3%
50%

Over 16 occurrences, 120-day forward avg gained 13.41%, beat the market by 5.94 pts; win rate 81.2%.

Filed revenue acceleration

Active · now 12.58%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

10 historical occurrences (since 2020-07-24)

Average forward return after Filed revenue acceleration

20-day: Win 88.9%, Sample 9, Median +3.42%, Excess +1.69%, Beat mkt rate 55.6%

60-day: Win 77.8%, Sample 9, Median +8.1%, Excess +1.86%, Beat mkt rate 55.6%

120-day: Win 62.5%, Sample 8, Median +13.18%, Excess +4.32%, Beat mkt rate 37.5%

120 days after: historical avg +12.79%

20-day +4.45%
60-day +4.96%
120-day +12.79%
20-day
60-day
120-day
Win
88.9%
77.8%
62.5%
Sample
9
9
8
Median
+3.42%
+8.1%
+13.18%
Excess
+1.69%
+1.86%
+4.32%
Beat mkt rate
55.6%
55.6%
37.5%

Over 8 occurrences, 120-day forward avg gained 12.79%, beat the market by 4.32 pts; win rate 62.5%.

EPS surprise beat

Active · now 20.91%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
33 historical occurrences (since 2015-04-30)

Average forward return after EPS surprise beat

20-day: Win 54.8%, Sample 31, Median +1.3%, Excess +0.22%, Beat mkt rate 48.4%

60-day: Win 71%, Sample 31, Median +4.1%, Excess +0.63%, Beat mkt rate 51.6%

120-day: Win 63.3%, Sample 30, Median +10.11%, Excess +2.64%, Beat mkt rate 50%

120 days after: historical avg +9.15%

20-day +0.29%
60-day +3.91%
120-day +9.15%
20-day
60-day
120-day
Win
54.8%
71%
63.3%
Sample
31
31
30
Median
+1.3%
+4.1%
+10.11%
Excess
+0.22%
+0.63%
+2.64%
Beat mkt rate
48.4%
51.6%
50%

Over 30 occurrences, 120-day forward avg gained 9.15%, beat the market by 2.64 pts; win rate 63.3%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 342+32.8% +34% 99.1% +17%
20-40 259-7.2% -16.4% 27% -20%
40-60 You are here303-14.5% -13.9% 20.1% -27.7%
60-80 203-6.3% -18.3% 22.7% -20.2%
80-100 317+34.2% +47.6% 77.3% +14.2%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 46.31, placing it in the 50.3 own-history percentile, inside the 40-60 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+11.8%
Win rate 66.4% Excess +5.6%
223d
Now
-12%
Win rate 25.4% Excess -15.9%
276d
+17.1%
Win rate 72.8% Excess +5%
408d
60-day momentum down
+15.5%
Win rate 69.3% Excess +7.4%
394d
-6.9%
Win rate 20.3% Excess -12.4%
192d
+34.6%
Win rate 96.1% Excess +20.1%
51d

Currently in “Middle × 60-day momentum up”: across 276 historical days, 120-day forward avg declined 12%, win rate 25.4%, lagged the market by 15.9%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.